Signs and symptoms of COVID‐19 in patients with multiple sclerosis

Schiavetti, Irene; Carmisciano, Luca; Ponzano, Marta; Cordioli, Cinzia; Cocco, Eleonora; Marfia, Girolama Alessandra; Inglese, Matilde; Filippi, Massimo; Radaelli, Marta; Bergamaschi, Roberto; Immovilli, Paolo; Capobianco, Marco; Rossi, Nicola De; Brichetto, Giampaolo; Scandellari, Cinzia; Cavalla, Paola; Pesci, Ilaria; Perini, Paola; Trojano, María; Lanzillo, Roberta; Tedeschi, Gioacchino; Comı, Gıancarlo; Battaglia, Mario Alberto; Patti, Francesco; Salvetti, Marco; Sormani, Maria Pia

doi:10.1111/ene.15554

Cited by 9 publications

(6 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, in another examination, it was demonstrated that among 39 MS patients with COVID-19, the distribution of psychiatric manifestations, such as depression and anxiety, is 10.25% (34). Correspondingly, several studies have reported neurologic symptoms in individuals diagnosed with both MS and COVID-19 (38)(39)(40).…”

Section: Discussionmentioning

confidence: 96%

Distinct Clinical Manifestations of COVID-19 in Multiple Sclerosis Patients: Unraveling the Clinical Nexus

Aboofazeli,

Mondeali,

Tajdini

et al. 2024

Arch Neurosci

View full text Add to dashboard Cite

Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is a virus in the coronaviridae, has caused a global pandemic with various symptoms and complications. Among the groups affected by this virus are individuals with multiple sclerosis (MS), a chronic autoimmune disorder that affects the primary central nervous system (CNS). Understanding coronavirus disease 2019’s (COVID-19) impact on MS patients is crucial for optimizing patient management and developing targeted therapies due to the challenges it presents. Objectives: The primary purpose of this study was to investigate the respiratory and neurology symptoms of COVID-19 in patients with MS in comparison to the non-infected group. Furthermore, this study examined how age and gender might affect the symptoms of contracting COVID-19 and the mortality rate in patients with MS. Methods: The data were collected from six hospitals within the Iranian Network for Research in Viral Diseases (INRVD) between March 2020 and July 2021. A total of 63 individuals diagnosed with MS were examined, with 30 testing positive for both COVID-19 and MS; however, 33 individuals were positive only for MS. These individuals had presented at the hospital experiencing respiratory symptoms, including rhinorrhea, difficulty breathing, and cough. Various clinical aspects were evaluated, including age, gender, and the presence of COVID-19 symptoms. Statistical analyses included the Mann-Whitney t-test, Fisher’s exact test, and odds ratio calculations using SPSS-27 and R 4.2.3. Results: The study encompassed 63 MS patients, with 29 (46%) and 34 (54%) males and females, respectively. Of these patients, 30 individuals were positive for COVID-19. Most subjects were from Tehran province, Iran. Patients in the case group were significantly younger than those in the control group. Notably, dizziness, breath shortness, and vomiting were significantly more prevalent in MS patients following COVID-19. Conclusions: This study highlights the distinct clinical presentation of COVID-19 in individuals with MS. Dizziness, breath shortness, vomiting, and increased mortality were significantly associated with MS patients with COVID-19. The aforementioned findings underscore the importance of tailored management strategies for this unique patient population following the disease.

show abstract

Section: Discussionmentioning

confidence: 96%

Distinct Clinical Manifestations of COVID-19 in Multiple Sclerosis Patients: Unraveling the Clinical Nexus

Aboofazeli,

Mondeali,

Tajdini

et al. 2024

Arch Neurosci

View full text Add to dashboard Cite

show abstract

“…In an Italian report of 1354 patients with MS and confirmed SARS-CoV-2 infection, the symptoms were similar to those without MS, such as fever, fatigue, cough, dyspnea, anosmia, and ageusia. However, the treatment for MS with the B cell-depleting anti-CD20 therapies (rituximab, ocrelizumab, ofatumumab, and ublituximab) [ 141 ], was associated with an increase in SARS-CoV-2 general symptoms, neurological disorders (weakness, fatigue, asthenia, and cognitive symptoms), conjunctivitis, and rash [ 142 ]. Recent data shows that patients on rituximab have a fourfold increased risk of SARS-CoV-2 hospitalizations [ 140 , 143 ].…”

Section: Reviewmentioning

confidence: 99%

“…Recent data shows that patients on rituximab have a fourfold increased risk of SARS-CoV-2 hospitalizations [ 140 , 143 ]. On the other hand, they reported a protective role with the use of teriflunomide, natalizumab, and fingolimod, reducing the shortness of breath, tachycardia, and chest pain, in patients with SARS-CoV-2 infection [ 142 ]. Some MS therapies, such as beta-interferons, fumarates, and sphingosine-1-phosphate (S1P), don’t seem to modify the course of COVID-19 infection.…”

Section: Reviewmentioning

confidence: 99%

The Neurological Implications of COVID-19: A Comprehensive Narrative Review

Cheyne,

Gopinath,

Muppa

et al. 2024

Cureus

View full text Add to dashboard Cite

The COVID-19 pandemic caused by the coronavirus SARS-CoV-2 revealed a huge number of problems as well as discoveries in medicine, notably, regarding the effects of the virus on the central nervous system (CNS) and peripheral nervous system (PNS). This paper is a narrative review that takes a deep dive into the complex interactions between COVID-19 and the NS. Therefore, this paper explains the broad range of neurological manifestations and neurodegenerative diseases caused by the virus. It carefully considers the routes through which SARS-CoV-2 reaches the NS, including the olfactory system and of course, the hematogenous route, which are also covered when discussing the virus's direct and indirect mechanisms of neuropathogenesis. Besides neurological pathologies such as stroke, encephalitis, Guillain-Barré syndrome, Parkinson’s disease, and multiple sclerosis, the focus area is also given to the challenges of making diagnosis, treatment, and management of these conditions during the pandemic. The review also examines the strategic and interventional approaches utilized to prevent these disorders, as well as the ACE2 receptors implicated in the mediation of neurological effects caused by COVID-19. This detailed overview, which combines research outputs with case data, is directed at tackling this pandemic challenge, with a view toward better patient care and outcomes in the future.

show abstract

“…AISM and FISM supported several data-sharing initiatives in the last years, promoting the development not only of the Italian MS Register, but also of databases to study different aspects of MS. This included initiatives such as the Italian Network of NeuroImaging (INNI) (47), the PROgnostic GEnetic Factors in Multiple Sclerosis (PROGEMUS) (48), the Multiple Sclerosis and COVID-19 (MuSC-19) platform (49), and Patient-Reported Outcome Measures for MS databases (PROMOPRO-MS) (50). Integration of PROMs with other outcomes will help to enable the holistic approach needed to unmask progression early in the disease.…”

Section: Italian Barcoding Ms Initiativementioning

confidence: 99%

The global patient-reported outcomes for multiple sclerosis initiative: bridging the gap between clinical research and care – updates at the 2023 plenary event

Zaratin,

Samadzadeh,

Seferoğlu

et al. 2024

Front. Neurol.

Self Cite

View full text Add to dashboard Cite

Significant advancements have been achieved in delineating the progress of the Global PROMS (PROMS) Initiative. The PROMS Initiative, a collaborative endeavor by the European Charcot Foundation and the Multiple Sclerosis International Federation, strives to amplify the influence of patient input on MS care and establish a cohesive perspective on Patient-Reported Outcomes (PROs) for diverse stakeholders. This initiative has established an expansive, participatory governance framework launching four dedicated working groups that have made substantive contributions to research, clinical management, eHealth, and healthcare system reform. The initiative prioritizes the global integration of patient (For the purposes of the Global PROMS Initiative, the term “patient” refers to the people with the disease (aka People with Multiple Sclerosis – pwMS): any individual with lived experience of the disease. People affected by the disease/Multiple Sclerosis: any individual or group that is affected by the disease: E.g., family members, caregivers will be also engaged as the other stakeholders in the initiative). insights into the management of MS care. It merges subjective PROs with objective clinical metrics, thereby addressing the complex variability of disease presentation and progression. Following the completion of its second phase, the initiative aims to help increasing the uptake of eHealth tools and passive PROs within research and clinical settings, affirming its unwavering dedication to the progressive refinement of MS care. Looking forward, the initiative is poised to continue enhancing global surveys, rethinking to the relevant statistical approaches in clinical trials, and cultivating a unified stance among ‘industry’, regulatory bodies and health policy making regarding the application of PROs in MS healthcare strategies.

show abstract

Signs and symptoms of COVID‐19 in patients with multiple sclerosis

Cited by 9 publications

References 35 publications

Distinct Clinical Manifestations of COVID-19 in Multiple Sclerosis Patients: Unraveling the Clinical Nexus

Distinct Clinical Manifestations of COVID-19 in Multiple Sclerosis Patients: Unraveling the Clinical Nexus

The Neurological Implications of COVID-19: A Comprehensive Narrative Review

The global patient-reported outcomes for multiple sclerosis initiative: bridging the gap between clinical research and care – updates at the 2023 plenary event

Contact Info

Product

Resources

About